Build status - In Progress

SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment

SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
Recruiting
18 years - 99 years
Male
Phase 3
10 participants needed
1 Location

Brief description of study

This is a research study for those with metastatic castration-resistant prostate cancer (mCRPC) that has progressed following treatment with prior therapy and cannot receive or refuse to receive chemotherapy. The purpose of this research study is to learn about the safety and effectiveness of 177Lu PNT2002, an investigational agent being studied for patients with mCRPC who have experienced disease progression following treatment with abiraterone, enzalutamide, apalutamide, or darolutamide.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Prostate Cancer
  • Age: 18 years - 99 years
  • Gender: Male

Male aged 18 years or older. Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate. Ineligible or averse to chemotherapeutic treatment options.

Updated on 04 Aug 2024. Study ID: 848625

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center